Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Location status: Recruiting
NCT Number: NCT06878859
The purpose of this study is to examine the feasibility, acceptability, and preliminary efficacy of a digital intervention for co-occurring cannabis use and depression. Participants will be randomized to complete Amplification of Positivity - Cannabis Use (AMP-C) or symptom tracking. The main outcomes will include changes in depressive symptoms and cannabis use, as well as usability ratings.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Boston, Massachusetts, 02114, United States
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
AMP-C is a smartphone-based digital intervention that includes activities that focus on positivity (e.g., noticing and capitalizing on positive events) to increase positive emotions, thoughts, and behaviors. The role and impact of CU on the maintenance of depression and reward dysfunction (and vice versa), is intertwined throughout the intervention.
Time frame: Baseline, Primary Endpoint: Post-Intervention (approximately one week after completing intervention), Secondary Endpoints: Intervention Midpoint (4 weeks into intervention), 1-, 3-, 6-, and 12-months after completing intervention
Depressive symptoms will be measured with the Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 is a widely-used 9-item self-report measure that assesses depressive symptom severity over the previous two weeks. Scores on the PHQ-9 range from 0-27, with greater scores indicating greater depression severity.
Time frame: Baseline, Primary Endpoint: Post-Intervention (approximately one week after completing intervention), Secondary Endpoints: Intervention Midpoint (4 weeks into intervention), 1-, 3-, 6-, and 12-months after completing intervention
Cannabis use use will be measured with the Daily Sessions, Frequency, Age of Onset, and Quantity of Cannabis Use Inventory (DFAQ-CU). The DFAQ-CU is a 24-item self-report measure that assesses frequency, age of onset, and quantity of cannabis use. There are six factors: daily sessions, frequency, age of onset, marijuana quantity, concentrate quantity, and edible quantity. The six factors, except age of onset, are independently scored, and higher scores indicate greater cannabis use. Our primary outcome will assess changes in frequency.
Time frame: Post-Intervention (approximately one week after completing intervention)
The System Usability Scale (SUS) is a 10-item self-report measure commonly used to assess the degree to which participants endorse ease of use following task-based operation of computer systems (i.e., perceived usability). Total scores on the SUS range from 0 to 100, with greater scores indicating greater usability. An average score of 68 or greater on the SUS in our AMP-C group will indicate acceptable usability.
Time frame: Post-Intervention (approximately one week after completing intervention)
Feasibility will be measured through the number of modules completed for the AMP-C group.
Time frame: Post-Intervention (approximately one week after completing intervention)
Feasibility will be measured through app usage time (hours).
Time frame: Daily for 8 weeks during intervention
Daily depressive symptoms will be measured with the Mobile Patient Health Questionnaire-9 (MPHQ-9). The MPHQ-9 is a modified version of the paper PHQ-9, which has been used in intensive sampling studies. Participants answer questions regarding their experience with the nine symptoms of MDD over the past 24 hours on a sliding scale. Total scores range from 0-900, with greater scores representing greater depression severity.
Time frame: Daily for 8 weeks during intervention
Daily cannabis use will be measured with a series of questions related to cannabis use consumption. These questions will capture frequency, quantity, product types, potencies, and administration methods of cannabis over the past 24 hours.
Time frame: Baseline, Primary Endpoint: Post-Intervention (approximately one week after completing intervention), Secondary Endpoints: Intervention Midpoint (4 weeks into intervention), 1-, 3-, 6-, and 12-months after completing intervention
The Positive and Negative Affect Schedule Scale-Positive Affect (PANAS-PA) is a 10-item self-report measure that assesses positive affect over the past week. Total scores range from 10-50, with greater scores representing greater positive affect.
Time frame: Baseline, Primary Endpoint: Post-Intervention (approximately one week after completing intervention), Secondary Endpoints: 1-, 3-, 6-, and 12-months after completing intervention
Anticipatory and consummatory anhedonia will be measured with the Temporal Experience of Pleasure Scale (TEPS). The TEPS is a 18-item self-report measure that assesses reward anticipation (e.g., motivation) and responsiveness (e.g., pleasure). There are two subscales in the TEPS: anticipatory anhedonia and consummatory anhedonia. Scores on the anticipatory subscale range from 10 to 60, and scores on the consummatory subscale range from 8 to 48. Higher scores indicate greater pleasure.
Time frame: Baseline, Primary Endpoint: Post-Intervention (approximately one week after completing intervention), Secondary Endpoints: 1-, 3-, 6-, and 12-months after completing intervention
The Positive and Negative Affect Schedule Scale-Negative Affect (PANAS-NA) is a 10-item self-report measure that assesses negative affect over the past week. Total scores range from 10-50, with greater scores representing greater negative affect.
Time frame: Continuously for 8 weeks during intervention
Passive sensing behaviors will be continuously collected without requiring participant input and will be related to behavioral activation (measured through GPS mobility). Changes in behaviors (e.g., increased GPS mobillity) will indicate greater behavioral activation during the course of the intervention for the AMP-C group.
Time frame: Baseline, Primary Endpoint: Post-Intervention (approximately one week after completing intervention), Secondary Endpoints: 1-, 3-, 6-, and 12-months after completing intervention
Reasons for drinking alcohol will be measured with the Drinking Motives Questionnaire-Revised (DMQR). The DMQR is a 20-item self-report measure that assesses common reasons for why people might drink alcohol. There are four subscales: Social, Coping, Enhancement, and Conformity. Subscale scores range from 1-25, with greater scores representing greater endorsement of specific reasons for drinking alcohol.
Time frame: Baseline, Primary Endpoint: Post-Intervention (approximately one week after completing intervention), Secondary Endpoints: 1-, 3-, 6-, and 12-months after completing intervention
Broader substance use will be measured with the Timeline Followback (TLFB). The TLFB is a self-report measure that assesses substance use and related behaviors over the past 30 days. Participants will be asked to identify the number of days over the 30 days in which they have consumed alcohol, tobacco/nicotine, opioids, stimulants, hallucinogens, sedatives/depressives, inhalants, and other illicit or prescription drugs. Total scores are not calculated, but the outcomes of interest include number of days per substance, with greater scores indicating a higher number of days of substance use in the past 30 days.
Time frame: Baseline, Primary Endpoint: Post-Intervention (approximately one week after completing intervention), Secondary Endpoints: 1-, 3-, 6-, and 12-months after completing intervention
Anxiety symptoms will be measured with the Generalized Anxiety Disorder-7 (GAD-7). The GAD-7 is a 7-item self-report measure that assesses anxiety symptom severity over the previous two weeks. Total scores range from 0-21, with higher scores representing higher anxiety severity.
Time frame: Baseline, Primary Endpoint: Post-Intervention (approximately one week after completing intervention), Secondary Endpoints: 1-, 3-, 6-, and 12-months after completing intervention
The Fear of Happiness Scale (FHS) is a 9-item self-report measure that assesses fear and apprehension of positivity due to its association with negative outcomes. Total scores range from 0-36, with greater scores representing greater fear of happiness.
Time frame: Baseline, Primary Endpoint: Post-Intervention (approximately one week after completing intervention), Secondary Endpoints: 1-, 3-, 6-, and 12-months after completing intervention
Dampening will be measured with the Responses to Positive Affect Scale (RPA; RPA) is a widely-used 17-item self-report measure that assesses dampening and amplifying of positive emotions. Scores on dampening subscale range from 8-32, with greater scores indicating greater dampening.
Time frame: Baseline, Primary Endpoint: Post-Intervention (approximately one week after completing intervention), Secondary Endpoints: 1-, 3-, 6-, and 12-months after completing intervention
The Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS) is a 14-item self-report measure developed to capture positive aspects of mental health in the general population. Participants indicate how often over the past two weeks they have experienced each statement on a five-point Likert scale ranging from 1 ("None of the time") to 5 ("All of the time"). Total scores range from 14 to 70, and greater scores reflect greater overall mental well-being.
Time frame: Baseline, Primary Endpoint: Post-Intervention (approximately one week after completing intervention), Secondary Endpoints: 1-, 3-, 6-, and 12-months after completing intervention
The Social Connectedness Scale - Revised (SCS-R) is a 20-item self-report measure that assesses individuals' sense of interpersonal closeness and belongingness with others. It captures the extent to which people feel emotionally connected to, understood by, and integrated within their social world. The SCS-R will be used to evaluate participants' perceived social connectedness and sense of belonging as an indicator of social and emotional well-being. Scores range from 20-120, with greater scores indicating greater social connectedness.
Time frame: Baseline, Primary Endpoint: Post-Intervention (approximately one week after completing intervention), Secondary Endpoints: 1-, 3-, 6-, and 12-months after completing intervention
The Valence Selection Task (VST) is a behavioral paradigm designed to assess cognitive-emotional biases in the processing of affective information, based on principles from Reward Devaluation Theory (RDT). The task involves presenting participants with incomplete reading prompts and requiring them to choose between three plausible sentence endings that differ in emotional valence, namely positive, negative, or neutral. This setup models a naturalistic decision-making scenario, akin to everyday reading or interpretation of emotional content. Outcome indices include propotion of positive, negative, or neutral choices selected, with lower proportion of selecting positive responses indicating greater reward devaluation.
Time frame: Baseline, Primary Endpoint: Post-Intervention (approximately one week after completing intervention), Secondary Endpoints: 1-, 3-, 6-, and 12-months after completing intervention
The Self-Referent Encoding Task (SRET) is a cognitive measure that assesses self-schemas and biases in processing emotional information. Participants view positive and negative adjectives and indicate whether each describes them ("Describes me?"), followed by a recall phase. The SRET evaluates endorsement, recall, and reaction time for self-referential words. Consistent with Reward Devaluation Theory, depressed individuals typically endorse and recall fewer positive and more negative self-descriptive words. The SRET will be used to assess self-referential processing and devaluation of positivity as indicators of cognitive-emotional functioning. Primary outcomes will include number of reponses of (1) "yes" and (2) "no" to self-referential positive words, with greater number of words for the former (1) indicating positive self-schemas and greater number of words for the latter (2) indicating devaluative self-schemas.
Massachusetts General Hospital
Other
AMP-C: A Digital Therapeutic for Reward Dysfunction in Co-Occurring Depression and Cannabis Use
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07453420
Anxiety, Anxiety Disorders
Haifa, Israel
View Trial DetailsNCT06920238
Anxiety, Anxiety Disorders
Lebanon, New Hampshire, United States
View Trial DetailsNCT07506070
Anxiety Disorders, Anxiety and Mood Disorders
View Trial DetailsNCT07188623
Behavior, Behavioral Activation Treatment
Stanford, California, United States
View Trial Details